

# Neurotrope

09:20 19 Feb 2016

## Neurotrope welcomes industry veteran to board

Neurotrope (OTCMKTS: NTRP), which is developing a disruptive therapy for the treatment of severe Alzheimer's disease, has appointed an industry veteran to the board.

Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity.

"We are very pleased to welcome Susanne to our board," said Charles S. Ramat, President and CEO of Neurotrope.

"She is an industry veteran with a tremendous scientific background including a dual Ph.D. in Chemistry and Biochemistry and extensive understanding of various therapeutic areas.

"Susanne's proven experience in scientific operations, strategic planning and managing the growth of emerging companies will prove invaluable as we advance Bryostatin-1 through our Phase 2b proof-of-concept trial in moderately-severe to severe Alzheimer's disease."

Wilke is the Co-founder and CEO of CrossBridge International, an advisory specializing in integrating proprietary scientific developments with sophisticated marketing and financing plans for biotech companies.

Dr. Wilke also served as Director of the Life Sciences group at Wombat Capital Markets SAS, a financial advisory firm specializing in cross-border transactions between the U.S. and Europe.

Neurotrope has successfully completed a Phase 2a trial, in which all primary endpoints were met, and is currently dosing patients in a Phase 2b proof-of-concept trial.

**Price:** US\$7.1

**Market Cap:** US\$91.75M

### 1 Year Share Price Graph



### Share Information

**Code:** NTRP

**Listing:** NASDAQ

**52 week High Low**  
**\$11.90 \$3.34**

**Sector:** Pharma & Biotech

**Website:** [www.neurotropebioscience.com](http://www.neurotropebioscience.com)

### Company Synopsis:

*Neurotrope operates as a clinical-stage biopharmaceutical and diagnostics company. Its two product platforms include a minimally-invasive diagnostic test for Alzheimer's disease and a drug candidate, known as bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage.*

### Author:

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

**action@proactiveinvestors.com**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

**No investment advice**

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any

specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.